Last reviewed · How we verify
MDX2301
At a glance
| Generic name | MDX2301 |
|---|---|
| Sponsor | ModeX Therapeutics, An OPKO Health Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MDX2301 CI brief — competitive landscape report
- MDX2301 updates RSS · CI watch RSS
- ModeX Therapeutics, An OPKO Health Company portfolio CI